ArticleInfection2026
Shortening of central venous catheter time in men with hematological and oncological diseases for prevention of central venous catheter-related bloodstream infections: a target-trial-emulation study.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PurposeIn patients with hematological malignancies and central venous catheters (CVC) men have a higher risk for CVC related bloodstream infections (CRBSI) than women. Hence, preventive strategies such as earlier CVC removal may reduce the overall CRBSI (oCRBSI) rate.MethodsA randomized simulation using data from a CVC registry was performed. Data were derived from unselected patients with hematological or oncological diseases and a CVC. Patients were randomized to an experimental (EXP-G) or control group (CON-G). For the men in the EXP-G, one-day increments of an earlier CVC removal were simulated based on actual data and compared to men in the CON-G without simulation. The primary endpoint was oCRBSI rate.ResultsUnderlying diseases were mainly hematological malignancies (87.3%). In the male patients with a median CVC in situ time of 13 days, the oCRBSI rate was 7.3% (103/1408), with 7.3% (53/729) in the EXP-G and 7.4% (50/679) in the CON-G. In the EXP-G, simulated shortening of CVC time by 1 day in men resulted in an oCRBSI rate of 5.2% compared with 7.4% in the CON-G (p = 0.12). Shortening CVC time by 2 days led to an oCRBSI rate of 4% (p = 0.008); the corresponding median CVC time was 11 days. A 3-day shortening further to 10 days reduced the oCRBSI rate to 2.7% (p < 0.001). Women from the same registry showed a 3.3% (30/920) oCRBSI rate after 12 days.ConclusionIn conclusion, shortening the CVC dwell time in men by 2 or 3 days, corresponding to a CVC duration of 10-11 days, reduces the CRBSI rate in men and mitigates the higher risk, compared to women.Clinical Trial Registration: SECRECY (Study to Evaluate Central Venous Catheter-related Infections in Hematology and Oncology) was registered within the German Clinical Trial Register (DRKS; no. DRKS00006551) on 29 September 2014.
Indexed as
Identifiers
42430117What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.